Subtherapeutic triazole concentrations as result of a drug-drug interaction with lumacaftor/ivacaftor

Colonization and infection with fungal species contribute to clinical disease in Cystic Fibrosis (CF) [1,2]. Antifungals in the triazole group, including itraconazole (ITR), posaconazole (POSA), and voriconazole (VOR) are used as therapeutic agents across the spectrum of fungal disease in CF. Since the clinical effect and the occurrence of adverse events with triazoles are correlated with plasma concentrations, therapeutic drug monitoring (TDM) is indicated. The efficacy of triazoles is predicted by the ratio between the area under the concentration-time curve (AUC) and the minimal inhibitory concentration (MIC) of the causative fungal pathogen (AUC/MIC) [3].

Source: Journal of Cystic Fibrosis - January 27, 2024 Category: Respiratory Medicine Authors: T.J.L. Smeets, H. van der Sijs, H.M. Janssens, E.J. Ruijgrok, B.C.M. de Winter Source Type: research